Irit Gliko-Kabir
Directeur Technique/Scientifique/R&D chez BIOLINERX LTD.
Postes actifs de Irit Gliko-Kabir
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOLINERX LTD. | Directeur Technique/Scientifique/R&D | 01/09/2017 | - |
Historique de carrière de Irit Gliko-Kabir
Anciens postes connus de Irit Gliko-Kabir
Sociétés | Poste | Début | Fin |
---|---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Directeur Technique/Scientifique/R&D | 01/07/2014 | - |
Formation de Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Statistiques
Internationale
Israël | 4 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Entreprise privées | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Bourse
- Insiders
- Irit Gliko-Kabir
- Expérience